Skip to content
Next results · Q4 2026Projected

10-K due Mar 8 – Apr 2

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 2 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 8 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$4.55M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Results day

Typical moveA typical move of 2.7% either way

Up after 3 of 9, down after 6.

The stock’s move from the last close before each release to the first close after it, over the last 9 releases. Largest: −9.4% after Q4 2025.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

10-Q filed
44 to 45 days
over its last 8
10-K filed
72 to 85 days
over its last 2

Based on 2 prior 10-K filings.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR